Genmab A (GMAB) Acquisitions (2024)
Genmab A's (GMAB) quarterly Acquisitions came in at -$1.8 billion in Q4 2024, little changed quarter-over-quarter from -$1.8 billion in Q3 2024.
Powered by 
Analysis
Genmab A (GMAB) Acquisitions (2024) Analysis & Trends
Genmab A (GMAB) has reported Acquisitions for 1 consecutive years, with -$1.8 billion the latest figure, recorded in Q4 2024.
- For the quarter ending Q4 2024, Acquisitions changed N/A year-over-year to -$1.8 billion; the trailing twelve-month figure through Jun 2025 stood at -$5.3 billion (changed N/A YoY), and the FY2025 full-year result was -$7.2 billion, changed N/A from the prior year.
- Acquisitions was little changed at -$1.8 billion in Q4 2024 per GMAB's latest filing, from -$1.8 billion in the prior quarter.
- Across five years, Acquisitions topped out at -$1.8 billion in Q2 2024 and bottomed at -$1.8 billion in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 11.21 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | - |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | - |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -1.78 Bn |
| Sep 30, 2024 | -1.78 Bn |
| Jun 30, 2024 | -1.78 Bn |